[go: up one dir, main page]

HK1136969A1 - 含非活性益新菌的婴儿产品 - Google Patents

含非活性益新菌的婴儿产品 Download PDF

Info

Publication number
HK1136969A1
HK1136969A1 HK10104424.6A HK10104424A HK1136969A1 HK 1136969 A1 HK1136969 A1 HK 1136969A1 HK 10104424 A HK10104424 A HK 10104424A HK 1136969 A1 HK1136969 A1 HK 1136969A1
Authority
HK
Hong Kong
Prior art keywords
inactivated
nutritional composition
probiotic
infant
viable
Prior art date
Application number
HK10104424.6A
Other languages
German (de)
English (en)
French (fr)
Other versions
HK1136969B (zh
Inventor
Udo Herz
Robert J. Mcmahon
William Michael Russell
Josef Neu
Original Assignee
Mjn U.S. Holdings Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39469924&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1136969(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mjn U.S. Holdings Llc filed Critical Mjn U.S. Holdings Llc
Publication of HK1136969A1 publication Critical patent/HK1136969A1/zh
Publication of HK1136969B publication Critical patent/HK1136969B/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • A61K35/741Probiotics
    • A61K35/744Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745Bifidobacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • A61K35/741Probiotics
    • A61K35/744Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747Lactobacilli, e.g. L. acidophilus or L. brevis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK10104424.6A 2007-02-28 2008-02-22 含非活性益新菌的婴儿产品 HK1136969B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90412207P 2007-02-28 2007-02-28
US60/904,122 2007-02-28
PCT/US2008/054717 WO2008106373A1 (en) 2007-02-28 2008-02-22 Product containing inactivated probiotic for children or infants

Publications (2)

Publication Number Publication Date
HK1136969A1 true HK1136969A1 (zh) 2010-07-16
HK1136969B HK1136969B (zh) 2013-02-22

Family

ID=

Also Published As

Publication number Publication date
RU2009135871A (ru) 2011-04-10
ES2388198T5 (es) 2020-07-14
BRPI0808145A2 (pt) 2021-03-23
EP2124977B1 (en) 2012-02-08
TWI418355B (zh) 2013-12-11
WO2008106372A1 (en) 2008-09-04
TWI494114B (zh) 2015-08-01
CA2676956A1 (en) 2008-09-04
EP2114423A1 (en) 2009-11-11
EP2124977A1 (en) 2009-12-02
US9408819B2 (en) 2016-08-09
PL2124977T3 (pl) 2012-07-31
BRPI0808052A2 (pt) 2014-06-24
CN105796607A (zh) 2016-07-27
MY145769A (en) 2012-04-13
CA2679374C (en) 2016-05-31
MX2009008875A (es) 2009-08-28
CN101636172A (zh) 2010-01-27
US20080206212A1 (en) 2008-08-28
TW200900075A (en) 2009-01-01
RU2468808C2 (ru) 2012-12-10
US9408818B2 (en) 2016-08-09
MX2009009119A (es) 2009-09-04
CA2676956C (en) 2017-06-13
RU2009135873A (ru) 2011-04-10
EP2124977B9 (en) 2012-05-02
ES2381232T3 (es) 2012-05-24
HK1141729A1 (zh) 2010-11-19
EP2114423B2 (en) 2020-01-01
MY151892A (en) 2014-07-14
EP2114423B1 (en) 2012-06-06
WO2008106373A1 (en) 2008-09-04
TW200906426A (en) 2009-02-16
CA2679374A1 (en) 2008-09-04
RU2468807C2 (ru) 2012-12-10
CN101678053A (zh) 2010-03-24
PL2114423T3 (pl) 2012-10-31
CN101678053B (zh) 2015-12-16
US20080206213A1 (en) 2008-08-28
ES2388198T3 (es) 2012-10-10
ATE544457T1 (de) 2012-02-15

Similar Documents

Publication Publication Date Title
EP2114423B2 (en) Inactivated lactobacillus rhammosus gg for treating systemic inflammation in infants
EP1868596B1 (en) Use of lactobacillus rhamnosus gg in combination with a long chain polyunsaturated fatty acid for the treatment, prevention or reduction of systemic inflammation in a formula-fed infant
US20060233752A1 (en) Method for treating or preventing systemic inflammation in formula-fed infants
HK1136969B (zh) 含非活性益新菌的婴儿产品
HK1227299A1 (zh) 用於兒童或嬰幼兒的含有滅活益生菌的產品
HK1227299A (zh) 用於儿童或婴幼儿的含有灭活益生菌的产品
HK1140430A (zh) 用於兒童或嬰幼兒的含有滅活益生菌的產品
HK1118471A (zh) 與長鏈多不飽和脂肪酸組合的鼠李糖乳杆菌用於治療、預防或減少配方喂養嬰兒的全身性炎症的用途
HK1141729B (zh) 用於治疗或预防全身性炎症的方法